Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Glaxosmithkline Pharmaceuticals Ltd

About the Company - Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3217.51 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2022.
PharmaceuticalsGSK House, Dr. Annie Besant Road, Mumbai Maharashtra
NamePosition Held
Ms. R S KarnadChairperson
Mr. B AkshikarManaging Director
Dr.(Ms.) S MaheshwariDirector
Mr. S WilliamsDirector
Mr. P V BhideDirector
Mr. A N RoyDirector
Mr. D SundaramDirector
Mr. M AnandDirector
Mr. J ChandyDirector

GlaxoSmithKline Pharmaceuticals Ltd. Share Price Update

Share PriceValue
Previous Day₹2,417.60

Basic Stock Data of Glaxosmithkline Pharmaceuticals Ltd

Market Cap 38,658 Cr.
Current Price 2,282
High / Low2,650/1,227
Stock P/E60.3
Book Value 90.9
Dividend Yield1.38 %
ROCE36.4 %
ROE26.8 %
Face Value 10.0

Data Source:

Competitors of Glaxosmithkline Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Achyut Healthcare Ltd 73.6 Cr. 52.560.8/24.6294 10.60.00 %2.63 %1.95 % 10.0
J B Chemicals & Pharmaceuticals Ltd 25,702 Cr. 1,6571,940/87550.0 1750.52 %22.4 %17.6 % 1.00
Par Drugs & Chemicals Ltd 260 Cr. 211248/12818.3 63.90.00 %23.0 %17.1 % 10.0
Shilpa Medicare Ltd 3,889 Cr. 448457/222 2050.00 %0.81 %1.71 % 1.00
Nectar Lifescience Ltd 927 Cr. 41.345.7/14.4114 47.60.00 %0.18 %6.01 % 1.00
Industry Average257.72 Cr150.7695.26100.420.1%9.8%8.87%4.6

Glaxosmithkline Pharmaceuticals Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit205181157133256198175149257229170144289
OPM %23%23%21%18%27%24%22%20%28%29%22%19%30%
Other Income-5542-79463041,322312212385428
Profit before tax127204601602681841,482163262224190181299
Tax %40%23%76%24%24%18%18%27%26%27%30%27%27%
Net Profit76157141212041501,219119193165133132218
EPS in Rs4.519.240.857.1512.068.8871.967.0411.429.717.887.8112.84

Glaxosmithkline Pharmaceuticals Ltd Quarterly Chart

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit802822528633478420508601657598762804832
OPM %33%31%21%19%17%14%18%19%20%20%23%25%25%
Other Income-1773020314912511970131-26291,401103132
Profit before tax6058347117565785115406833065252,093839894
Tax %29%33%32%37%35%34%35%35%70%32%19%27%
Net Profit429562482476376337351445933581,695611648
EPS in Rs25.3033.1728.4328.1222.2019.8820.7026.295.5021.14100.0436.0538.24
Dividend Payout %89%75%88%111%113%75%85%76%727%142%90%89%

Glaxosmithkline Pharmaceuticals Ltd Profit & Loss Yearly Chart

Glaxosmithkline Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:2%
5 Years:3%
3 Years:0%
Compounded Profit Growth
10 Years:-1%
5 Years:12%
3 Years:44%
Stock Price CAGR
10 Years:5%
5 Years:12%
3 Years:18%
1 Year:90%
Return on Equity
10 Years:27%
5 Years:34%
3 Years:46%
Last Year:27%

Glaxosmithkline Pharmaceuticals Ltd Balance Sheet

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital85858585858585169169169169169169
Other Liabilities1,0891,0771,1361,3848699951,8891,7711,3121,6021,9501,5701,709
Total Liabilities3,0303,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,270
Fixed Assets9989100123204258325432758387331330318
Other Assets2,8022,9002,9582,9772,5772,1402,7002,4772,2552,7153,9072,4582,412
Total Assets3,0303,0883,1303,2163,0553,0043,9473,9113,1333,1154,6333,3273,270

Glaxosmithkline Pharmaceuticals Ltd Reserves and Borrowings Chart

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 335314281338139234473409490578811484
Cash from Investing Activity 358-110189180499301-104-153-57418-406808
Cash from Financing Activity -395-441-494-497-638-511-307-358-428-696-524-1,543
Net Cash Flow299-237-2421-02462-1026300-119-251

Glaxosmithkline Pharmaceuticals Ltd Financial Efficiency Indicators

MonthDec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days131614111621191411272322
Inventory Days1329410991156111147131135159144131
Days Payable807890749773149109100135156122
Cash Conversion Cycle663233277560173646501131
Working Capital Days-49-42-45-48267-90-72-38-37-92-55
ROCE %48%50%34%42%29%22%26%31%33%38%37%36%

Glaxosmithkline Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Glaxosmithkline Pharmaceuticals Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
No. of Shareholders1,19,9521,20,4761,21,4451,23,4801,10,1411,12,9641,16,6511,20,1271,20,4151,19,0321,15,2681,14,663

Glaxosmithkline Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Glaxosmithkline Pharmaceuticals Ltd Shareholders

Glaxosmithkline Pharmaceuticals Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Aditya Birla Sun Life ELSS Tax Saver Fund12188721.42201.98
Nippon India Pharma Fund8539072.28141.5
ICICI Prudential Large & Mid Cap Fund8391791.44139.06
SBI Magnum Midcap Fund8068950.93133.71
Aditya Birla Sun Life MNC Fund - Div7536003.58124.88
Aditya Birla Sun Life MNC Fund - Gr7536003.58124.88
ICICI Prudential Multi Asset Fund7532570.45124.82
Nippon India Growth Fund5590000.4392.63
ICICI Prudential Value Discovery Fund3551840.1758.86
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund2938141.4848.69

Glaxosmithkline Pharmaceuticals Ltd ROCE Trend

Glaxosmithkline Pharmaceuticals Ltd EPS Trend

Glaxosmithkline Pharmaceuticals Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)36.0899.2931.355.5026.29
Diluted EPS (Rs.)36.05100.0421.145.5026.29
Cash EPS (Rs.)39.93104.0625.7810.3829.16
Book Value[Excl.RevalReserv]/Share (Rs.)102.79157.1987.26107.47126.31
Book Value[Incl.RevalReserv]/Share (Rs.)102.79157.1987.26107.47126.31
Revenue From Operations / Share (Rs.)191.95193.50172.70190.33184.65
PBDIT / Share (Rs.)53.4249.4541.8443.4641.50
PBIT / Share (Rs.)49.5445.4237.2038.5838.64
PBT / Share (Rs.)49.3745.9926.8018.0540.30
Net Profit / Share (Rs.)36.05100.0421.145.5026.29
NP After MI And SOA / Share (Rs.)36.41100.0421.145.5026.29
PBDIT Margin (%)27.8225.5524.2222.8322.47
PBIT Margin (%)25.8023.4721.5320.2620.92
PBT Margin (%)25.7223.7615.519.4821.82
Net Profit Margin (%)18.7851.6912.242.8914.23
NP After MI And SOA Margin (%)18.9651.6912.242.8914.23
Return on Networth / Equity (%)35.4163.6424.225.1120.81
Return on Capital Employeed (%)41.9526.2135.8030.9526.63
Return On Assets (%)18.5336.5711.492.9711.38
Asset Turnover Ratio (%)0.800.830.930.910.79
Current Ratio (X)1.882.181.631.741.38
Quick Ratio (X)1.531.871.221.261.05
Inventory Turnover Ratio (X)0.811.040.890.971.38
Dividend Payout Ratio (NP) (%)247.2129.98189.20363.5166.56
Dividend Payout Ratio (CP) (%)223.3928.82155.15192.6360.01
Earning Retention Ratio (%)-147.2170.02-89.20-263.5133.44
Cash Earning Retention Ratio (%)-123.3971.18-55.15-92.6339.99
Interest Coverage Ratio (X)499.36419.65200.69116.211268.47
Interest Coverage Ratio (Post Tax) (X)336.84185.96131.2269.61752.75
Enterprise Value (Cr.)21275.9725686.8623243.3020012.1020849.07
EV / Net Operating Revenue (X)6.547.847.946.216.67
EV / EBITDA (X)23.5130.6732.8027.1829.65
MarketCap / Net Operating Revenue (X)6.908.598.346.547.04
Retention Ratios (%)-147.2170.01-89.20-263.5133.43
Price / BV (X)12.8810.5816.5111.5910.29
Price / Net Operating Revenue (X)6.908.598.346.547.04

Glaxosmithkline Pharmaceuticals Ltd Profitability Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Liquidity Ratios

Glaxosmithkline Pharmaceuticals Ltd Liquidity Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Interest Coverage Ratios (%)

Glaxosmithkline Pharmaceuticals Ltd Valuation Ratios

Fair Value of Glaxosmithkline Pharmaceuticals Ltd Stock

Fair Value: ₹1489.25

The stock is overvalued by 34.74% compared to the current price ₹2282

*Investments are subject to market risks

Strength and Weakness of Glaxosmithkline Pharmaceuticals Ltd Stock

  1. The stock has a high average ROCE of 35.50%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -44.58, which is a positive sign.
  3. The company has higher reserves (1,829.38 cr) compared to borrowings (8.85 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (2.46 cr) and profit (598.77 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 41.88 and average Dividend Yield of 22.40%.
  2. The stock has a high average Cash Conversion Cycle of 40.33, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glaxosmithkline Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE